TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.

Adam J Luginbuhl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.